New Clinical Trials for Pancreatic Cancer Are Giving Doctors Hope

Pancreatic cancer has proven one of the most challenging cancers to treat, with low survival rates and limited treatment options. However, a wave of innovative clinical trials is now offering new possibilities for pancreatic cancer patients, including those affected by 9/11-related exposures. Advances in targeted therapies, precision medicine, and immunotherapy are changing the world of pancreatic cancer care. For individuals diagnosed after being exposed in the aftermath of the 9/11 terrorist attacks, these advances bring with them hope for more positive outcomes and better treatment options for individuals diagnosed with pancreatic cancer.

The Role of Clinical Trials in Pancreatic Cancer Treatment

Clinical trials are essential for testing new treatments and improving care for patients with pancreatic cancer, contributing to broader medical knowledge that could enhance long-term survival rates. In addition, by participating in clinical trials, patients with pancreatic cancer can gain access to breakthrough therapies that are not yet offered through regular medical channels. Patients may benefit from targeted approaches when traditional treatments fail.

What’s Changing in Clinical Trials for Pancreatic Cancer

Clinical trials are studying the genetic makeup of pancreatic tumors so clinicians can target treatments toward stopping each patient’s biologically unique cancer. This is known as molecular profiling to guide therapy, a practice commonly used in other cancers. This precision medicine approach provides for higher efficacy and fewer side effects.

Targeted therapy uses drugs or other substances to specifically attack molecules that cancer cells need to grow and survive. Pancreatic ductal adenocarcinoma (PDAC), the most common and the hardest type of pancreatic cancer to treat, develops when genes in the RAS family are altered. Researchers have long considered RAS to be “undruggable”, but that is changing, and new clinical trials are focusing on common genetic mutations such as KRAS. Drugs targeting KRAS are showing preliminary promise in clinical phase II/III trials. These advances are essential as over 90% of patients with PDAC have tumors carrying a mutation in a type of RAS gene, known as KRAS.

Researchers are also pairing immunotherapies with RAS multi-selective inhibitors to enhance immune system activation against pancreatic tumors. 

What These Trials Mean for Pancreatic Cancer Patients

For newly diagnosed patients or those with recurrent cancer, clinical trials offer a chance to receive novel treatment while contributing to future care advancements. Though eligibility criteria can vary, trials often target patients with specific genetic markers or those whose disease hasn’t responded to standard treatments. Participants gain access to thorough monitoring and care, and in some cases, enjoy longer progression-free survival or improved quality of life.

Legal Considerations for Clinical Trial Participants

Participation in clinical trials is voluntary, and participants should be well-informed of all aspects. Patients must review the consent process and fully understand potential benefits, risks, and the various financial and legal protections available. Individuals filing claims through the September 11th Victim Compensation Fund (VCF) or those accessing care through the World Trade Center Health Program (WTCHP) must ensure that trial participation supports their health record and the documentation needed for certification and compensation. Collaborating with medical and legal experts helps preserve eligibility for any related VCF claims or future benefits.

What to Do If You or a Loved One Is Considering a Trial

Here are some essential steps to take when considering a clinical trial:

1. Inquire About Eligibility: Request genetic profiling to check for mutations like KRAS and other markers that qualify you for specific trials.
2. Talk to Your Oncologist: Discuss the parameters of the trial with your oncologist. 
3. Consult Legal Counsel: Ensure participation doesn’t interfere with WTCHP certification or VCF claims; legal experts can guide you to ensure proper documentation of your treatment.
4. Understand Potential Costs: Some trial-related care might be covered; ask about financial assistance, insurance obligations, and what out-of-pocket costs you may face.

Hope is on the Horizon for 9/11 Pancreatic Cancer

The clinical trial landscape for pancreatic cancer is evolving rapidly. For those affected by the 9/11 attacks and diagnosed with this pancreatic cancer, opportunities to participate in cutting-edge research could change the course of treatment and health outcomes. When combined with WTCHP support and financial compensation through the VCF, patients can pursue the most innovative options for treatment without jeopardizing their care or eligibility for benefits. If you or a loved one is exploring clinical trials related to a certified 9/11 condition, reach out to an experienced 9/11 attorney at Hansen & Rosasco, LLP to ensure you’re fully supported on your journey.